An open-label expanded-access trial of bendamustine in patients with rituximab-refractory indolent non-Hodgkin lymphoma or previously untreated chronic lymphocytic leukemia: BEND-ACT

BACKGROUND: Bendamustine is a bifunctional alkylating agent with unique properties that distinguish it from other agents in its class. Bendamustine is used as monotherapy or in combination with other agents to treat patients with non-Hodgkin lymphoma (nhl) and chronic lymphocytic leukemia (cll). MET...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Curr Oncol
Autors principals: Kouroukis, C.T., Crump, M., MacDonald, D., Larouche, J.F., Stewart, D.A., Johnston, J., Sauvageau, S., Beausoleil, E., Sage, P., Dubois, S.G., Christofides, A., Di Clemente, S., Sehn, L.
Format: Artigo
Idioma:Inglês
Publicat: Multimed Inc. 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4530811/
https://ncbi.nlm.nih.gov/pubmed/26300664
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3747/co.22.2431
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars